Clinical trial of propofol injection in the treatment of hyperactive delirium
10.13699/j.cnki.1001-6821.2017.05.007
- VernacularTitle:丙泊酚注射剂治疗活动过多型谵妄的临床研究
- Author:
Ying WU
1
;
Shu-Hong LIU
;
Ya-Jing LIU
;
Hong-Shan KANG
;
Li PENG
Author Information
1. 哈励逊国际和平医院重症医学科
- Keywords:
propofol injection;
hyperactive delirium;
safety
- From:
The Chinese Journal of Clinical Pharmacology
2017;33(5):408-410
- CountryChina
- Language:Chinese
-
Abstract:
Objective To observe the clinical efficacy and safety of propofol injection in the treatment of hyperactive delirium.Methods One hundred patients with hyperactive delirium were randomly divided into control group (n =48 cases) and treatment group (n =52 cases).Control group was given loading dose of 1 μg · kg-1 dexmedetomidine for 10 min with intravenous push,then continuous intravenous infusion for 10 min with 0.52-0.70 μg · kg-1 · h-1.Treatment group was given 0.5 mg · kg-1propofol with intravenous push,then continuous intravenous infusion for 5 min with 0.5-1.0 μg · kg-1 · h-1 Two groups were treated for 2 h.The clinical efficacy and adverse drug reactions were compared between two groups.Results After treatment,the main indexes in treatment and control groups were compared between two groups:the intensive care delirium screening checklist were (1.26 ± 0.57),(2.53 ± 0.76) points;total delirium duration were (20.15 ±4.67),(26.46 ± 5.12)h;duration of restless delirium were (8.32 ± 2.48),(12.32 ± 4.14) h;delirium recurrence rates were 3.85％,18.75％;duration of mechanical ventilation were (50.65±8.84),(60.67 ± 7.98) h;extubation time were (52.76 ± 7.98),(62.38 ± 8.95) h;intensive care unit time were (114.59 ± 10.76),(123.43 ± 9.87) h,with significant difference (P ＜ 0.05).The adverse drug reactions in two groups were based on hypotension,bradycardia and acute dystonia.The incidences of adverse drug reactions in treatment and control groups were 21.15％ and 27.08％ without significant difference (P ＜ 0.05).Conclusion Propofol injection has a definitive clinical efficacy in the treatment of hyperactive delirium,without increasing the incidence of adverse drug reactions.
